{
    "clinical_study": {
        "@rank": "109141", 
        "arm_group": {
            "arm_group_label": "Single Arm - Healthy Volunteers", 
            "arm_group_type": "Experimental", 
            "description": "Etarfolatide (EC20)"
        }, 
        "brief_summary": {
            "textblock": "A Phase 1, single-center, open-label, single arm, baseline-controlled (for safety) study in\n      normal volunteers.  Study will determine biodistribution and excretion of the radioactive\n      drug substance and evaluate the safety and tolerability of 99mTC-Etarfolatide in normal\n      volunteers."
        }, 
        "brief_title": "Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be 18 years of age or older.\n\n          -  Subject must not have any major health problems as deemed by principal investigator.\n\n          -  Subject must provide informed consent prior to enrollment.\n\n        Exclusion Criteria:\n\n          -  Subject is pregnant or breast-feeding.\n\n          -  Subject is simultaneously participating in another investigative drug or device\n             study.\n\n          -  Subject must have completed the follow-up phase of any previous study at least 30\n             days prior to enrollment in this study.\n\n          -  Subject has a known history of chronic abuse of drugs or alcohol or tests positive in\n             pre-study urine drug abuse screen.\n\n          -  Subject is currently taking folic acid supplements and cannot stop taking the\n             supplements for a period of 8 days (7 days prior to the study and one day after last\n             imaging procedure).\n\n          -  Subject's physical condition unsuitable for radionuclide imaging.\n\n          -  Subject has been administered another radiopharmaceutical that would interfere with\n             the assessment of the biodistribution of 99mTc-etarfolatide."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748864", 
            "org_study_id": "EC20.11"
        }, 
        "intervention": {
            "arm_group_label": "Single Arm - Healthy Volunteers", 
            "intervention_name": "Etarfolatide (EC20)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Volunteers", 
        "lastchanged_date": "December 12, 2012", 
        "number_of_arms": "1", 
        "official_title": "A Single-Center Phase I Clinical Study to Evaluate The Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers", 
        "other_outcome": {
            "description": "Comparison made of SPECT images taken of volunteers who received folic acid injection prior to 99mTc-EC20 injection and those who did not receive folic acid injection.\nReadability of scans, background \"noise\" as well as evaluation of any other differences will be noted.", 
            "measure": "Quality of SPECT images of Normal Volunteers with or without injection of Folic Acid", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "overall_contact": {
            "email": "bnguyen@endocyte.com", 
            "last_name": "Binh Nguyen, MD, PhD", 
            "phone": "317-846-1478", 
            "phone_ext": "1216"
        }, 
        "overall_official": {
            "affiliation": "Horizon Oncology Research, Inc.", 
            "last_name": "Wael Harb, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To track biodistribution of 99mTc-EC20 injection, blood and urine samples will be collected at set times within the first 24hrs post 99mTc-EC20 injection for all patients and radioactivity measured.", 
                "measure": "Biodistribution of Radioactive Drug Substance", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "To track excretion of 99mTc-EC20 injection, blood and urine samples will be collected at set times within the first 24hrs post 99mTc-EC20 injection for all patients and radioactivity measured.", 
                "measure": "Excretion of Radioactive Drug Substance", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748864"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Asses any adverse events and serious adverse events experienced by volunteers.", 
                "measure": "Safety of 99mTc-Etarfolatide in Normal Volunteers", 
                "safety_issue": "Yes", 
                "time_frame": "4 days post-injection of EC20"
            }, 
            {
                "description": "Asses any adverse events and serious adverse events experienced by volunteers.", 
                "measure": "Tolerability of 99mTc-Etarfolatide in Normal Volunteers", 
                "safety_issue": "Yes", 
                "time_frame": "4 days"
            }
        ], 
        "source": "Endocyte", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Endocyte", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}